J&J iBOT 3000
This article was originally published in The Gray Sheet
Executive Summary
National coverage determination will be sought for the stair-climbing wheelchair to enable payments beyond those provided by existing Medicare codes for power wheelchairs, according to the firm. The $29,000 device received PMA approval Aug. 13 (1"The Gray Sheet" Aug. 18, 2003, p. 3)...
You may also be interested in...
J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.